ANKLE2 Inhibitors
Chemical inhibitors of ANKLE2 can function through various mechanisms, primarily by disrupting the cell cycle and signaling pathways in which ANKLE2 is involved. Paullone, roscovitine, olomoucine II, and purvalanol A are compounds that inhibit cyclin-dependent kinases (CDKs), a group of enzymes critical for the regulation of the cell cycle. This inhibition can prevent the phosphorylation of proteins essential for cell cycle progression, thereby indirectly affecting ANKLE2's role in controlling cellular division and maintenance. Similarly, AZD7762, a checkpoint kinase inhibitor, can halt ANKLE2 functions linked to the cell cycle's checkpoint controls and DNA repair mechanisms. By preventing the activation of these checkpoints, it disrupts the orderly progression of the cell cycle where ANKLE2 operates.
Other chemical inhibitors target different signaling pathways that regulate cellular responses where ANKLE2 is implicated. SP600125 interferes with the JNK pathway, a part of MAPK signaling, which can affect ANKLE2's participation in cellular responses to external stresses. PD98059 and SB203580 are inhibitors of the MEK and p38 MAP kinase, respectively, and by targeting these kinases, they can influence ANKLE2's activity in stress response and other pathways regulated by MAPK signaling. The RSK kinase inhibitor BI-D1870 also acts upon a component of the MAPK pathway, which can impact ANKLE2's regulatory actions. Y-27632, a ROCK inhibitor, affects cytoskeletal organization, potentially altering ANKLE2's role in cytoskeleton-associated processes. Lastly, LY294002 and wortmannin are PI3K inhibitors that can disrupt the PI3K/Akt signaling pathway, thus impacting ANKLE2's function in processes regulated by this pathway, including various aspects of cellular growth and survival. Each of these inhibitors, by targeting specific enzymes and pathways, can modulate ANKLE2's involvement in the intricate network of cellular regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Paullone is a cyclin-dependent kinase inhibitor. By inhibiting cyclin-dependent kinases which play a crucial role in cell cycle regulation, Paullone can disrupt the phosphorylation events necessary for ANKLE2 function, as ANKLE2 is involved in cell division and its activity is regulated during the cell cycle. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine selectively inhibits CDKs, which are important for the regulation of cell cycle progression. Since ANKLE2 has a role in cell cycle control, inhibiting these kinases can result in the impairment of the cell cycle-related functions of ANKLE2. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A is another potent CDK inhibitor. Its action can lead to an indirect inhibition of ANKLE2 by altering the cell cycle progression and therefore disrupting the processes in which ANKLE2 is involved. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK signaling pathway. As ANKLE2 is known to be involved in mechanisms that are regulated by MAPK signaling, the inhibition of JNK can lead to the disruption of ANKLE2's functional role in these processes. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that affects cytoskeletal organization. Given that ANKLE2 is involved in the regulation of cytoskeleton-related processes, the inhibition of ROCK may result in the disruption of ANKLE2's role in these processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor which disrupts PI3K/Akt signaling. Since ANKLE2 has a role in processes regulated by this pathway, inhibiting PI3K can lead to the functional inhibition of ANKLE2 activity related to this signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, and it can inhibit the function of ANKLE2 by interrupting the PI3K/Akt signaling pathway, which is known to regulate processes involving ANKLE2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. Inhibition of this pathway can lead to the disruption of ANKLE2's functional role, as ANKLE2 is associated with processes that are regulated by the MAPK/ERK pathway. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB203580 inhibits p38 MAP kinase, which is involved in cellular stress responses. ANKLE2, functioning in various stress response-related pathways, can be indirectly inhibited through the inhibition of p38 MAP kinase activity. | ||||||
BI-D1870 | 501437-28-1 | sc-397022 sc-397022A | 1 mg 5 mg | $92.00 $260.00 | 12 | |
BI-D1870 is a potent inhibitor of the RSK kinases, downstream effectors in the MAPK pathway. As ANKLE2 is involved in cellular processes regulated by MAPK signaling, inhibiting RSKs could disrupt ANKLE2's function in these processes. | ||||||